Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AmacaThera and Pacira sign agreement for AMT-143
This agreement will involve the development and commercialisation of the anaesthetic intended for managing postoperative pain. The deal includes $5m upfront to AmacaThera and up to $225m in
This agreement will involve the development and commercialisation of the anaesthetic intended for managing postoperative pain. The deal includes $5m upfront to AmacaThera and up to $225m in
Sativex is indicated for the enhancement of symptoms in adult patients experiencing moderate to severe spasticity due to multiple sclerosis (MS) who have not responded sufficiently to other
This topical, steroid-free formulation is applied once daily and can be used for long-term disease control without limits on duration or body surface area. Clinical trials have shown
The agreement covers Samsung Bioepis’ two ophthalmology assets, Byooviz (ranibizumab) and Opuviz (aflibercept), in Europe. The transfer returns commercial rights for Byooviz to Samsung Bioepis and positions the
This tripartite agreement leverages expertise in cell immunotherapies, peptide HLA (pHLA) binder discovery, and bispecific T cell engagers, with the aim of overcoming challenges to achieving durable cancer
Following expansion, the site will cover over 200,000ft² and feature new technologies in sustainably designed facilities. The initial phase of expansion comprises a 31,000ft² building that will accommodate
The deal advances Biogen’s immunology strategy, focussing on established immune mechanisms that may address inflammatory disorders with considerable unmet need. Biogen’s early-stage immunology pipeline is bolstered by the
The focus of this partnership is to create a new vaccine utilising a non-replicating highly attenuated vaccinia virus, designed to enhance safety and reduce the risk of emergence
This comes just two weeks after its US Food and Drug Administration (FDA) approval. The approval is based on results from FIBRONEER-IPF, a Phase III trial in IPF
In preclinical and Phase I studies in healthy participants, PORT-77 demonstrated a substantial reduction of plasma protoporphyrin IX (PPIX) through rapid ABCG2 inhibition. This outcome has the potential